BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Huang C, Dai C, Yeh M, Huang C, Tai C, Hsieh M, Liang P, Lin Y, Hsieh M, Yang H, Huang J, Lin Z, Chen S, Yu M, Chuang W. Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. Journal of Hepatology 2015;62:512-8. [DOI: 10.1016/j.jhep.2014.10.011] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 3.6] [Reference Citation Analysis]
Number Citing Articles
1 Jang TY, Yeh ML, Huang CI, Lin ZY, Chen SC, Hsieh MH, Dai CY, Huang JF, Huang CF, Chuang WL, Yu ML. Association of hyperuricemia with disease severity in chronic hepatitis C patients. PLoS One 2018;13:e0207043. [PMID: 30395654 DOI: 10.1371/journal.pone.0207043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
2 Tamaki N, Kurosaki M, Higuchi M, Takada H, Nakakuki N, Yasui Y, Suzuki S, Tsuchiya K, Nakanishi H, Itakura J. Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. PLoS One. 2015;10:e0137351. [PMID: 26352693 DOI: 10.1371/journal.pone.0137351] [Cited by in Crossref: 18] [Cited by in F6Publishing: 14] [Article Influence: 2.6] [Reference Citation Analysis]
3 Gastaldi G, Goossens N, Clément S, Negro F. Current level of evidence on causal association between hepatitis C virus and type 2 diabetes: A review. J Adv Res 2017;8:149-59. [PMID: 28149650 DOI: 10.1016/j.jare.2016.11.003] [Cited by in Crossref: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.8] [Reference Citation Analysis]
4 Huang CF, Yu ML. Treating hepatitis C in the elderly: pharmacotherapeutic considerations and developments. Expert Opin Pharmacother 2017;18:1867-74. [PMID: 29086615 DOI: 10.1080/14656566.2017.1400010] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.8] [Reference Citation Analysis]
5 Magri MC, Manchiero C, Prata TVG, Nunes AKDS, Oliveira Junior JS, Dantas BP, Tengan FM. The influence of gene-chronic hepatitis C virus infection on hepatic fibrosis and steatosis. Diagn Microbiol Infect Dis 2020;97:115025. [PMID: 32147132 DOI: 10.1016/j.diagmicrobio.2020.115025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
6 Jiménez-Sousa MA, Berenguer J, García-Álvarez M, Gutierrez-Rivas M, Aldámiz-Echevarria T, Tejerina F, Diez C, Vázquez-Morón S, Resino S. Impact of patatin-like phospholipase domain-containing 3 gene polymorphism (rs738409) on severity of liver disease in HIV/hepatitis C virus-coinfected patients. AIDS 2016;30:465-70. [PMID: 26760234 DOI: 10.1097/QAD.0000000000000908] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
7 Huang CF, Chen JJ, Yeh ML, Huang CI, Hsieh MY, Yang HL, Dai CY, Huang JF, Lin ZY, Chen SC. PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. Sci Rep. 2015;5:11901. [PMID: 26139292 DOI: 10.1038/srep11901] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
8 Yu ML. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol 2016;64:981-2. [PMID: 26795827 DOI: 10.1016/j.jhep.2015.12.022] [Reference Citation Analysis]
9 Aizawa Y, Seki N, Nagano T, Abe H. Chronic hepatitis C virus infection and lipoprotein metabolism. World J Gastroenterol 2015; 21(36): 10299-10313 [PMID: 26420957 DOI: 10.3748/wjg.v21.i36.10299] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
10 Huang CF, Yeh ML, Huang CI, Lin ZY, Chen SC, Huang JF, Dai CY, Chuang WL, Chen JJ, Yu ML. Tolloid-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. Sci Rep 2018;8:15058. [PMID: 30305682 DOI: 10.1038/s41598-018-33448-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
11 Desbois AC, Cacoub P. Diabetes mellitus, insulin resistance and hepatitis C virus infection: A contemporary review. World J Gastroenterol 2017; 23(9): 1697-1711 [PMID: 28321170 DOI: 10.3748/wjg.v23.i9.1697] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 39] [Article Influence: 9.4] [Reference Citation Analysis]
12 Huang CF, Huang CI, Yeh ML, Hou C, Hou NJ, Hsieh MY, Huang JF, Chen SC, Lin ZY, Dai CY, Chuang WL, Yu ML. Disease severity and erythropoiesis in chronic hepatitis C. J Gastroenterol Hepatol 2017;32:864-9. [PMID: 27637864 DOI: 10.1111/jgh.13600] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
13 Zhu XB, Zhuo LY, Yue M, Liu M, Zang F, Fan HZ, Wu JJ, Xia XS, Zhang AM, Yu RB, Huang P. Genetic variants in IFIH1 and DDX58 influence hepatitis C virus clearance in Chinese Han population. J Med Virol 2019;91:1097-103. [PMID: 30633820 DOI: 10.1002/jmv.25398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
14 Yen YH, Tsai MC, Wu CK, Chang KC, Hung CH, Chiu KW, Lu SN, Wang JH, Chen CH, Kee KM, Kuo YH, Tseng PL, Lin MT, Huang CM, Lin JT, Hu TH. Association between PNPLA3 (rs738409 C>G) variant and hepatocellular carcinoma in Asian chronic hepatitis C patients: A longitudinal study. J Formos Med Assoc 2018;117:833-40. [PMID: 29089161 DOI: 10.1016/j.jfma.2017.10.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
15 Jiao J, Watt GP, Lee M, Rahbar MH, Vatcheva KP, Pan JJ, McCormick JB, Fisher-Hoch SP, Fallon MB, Beretta L. Cirrhosis and Advanced Fibrosis in Hispanics in Texas: The Dominant Contribution of Central Obesity. PLoS One 2016;11:e0150978. [PMID: 26950933 DOI: 10.1371/journal.pone.0150978] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
16 Huang CF, Huang CI, Yeh ML, Wang SC, Chen KY, Ko YM, Lin CC, Tsai YS, Tsai PC, Lin ZY, Chen SC, Dai CY, Huang JF, Chuang WL, Yu ML. Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. Oncotarget 2017;8:32618-25. [PMID: 28427234 DOI: 10.18632/oncotarget.15941] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
17 Huang CF, Chuang WL, Yu ML. Interference of diabetes on the association of γ-glutamyl transpeptidase to platelet ratio with liver fibrosis in chronic hepatitis C. Kaohsiung J Med Sci 2016;32:334-5. [PMID: 27377848 DOI: 10.1016/j.kjms.2016.04.004] [Reference Citation Analysis]
18 Huang CI, Huang CF, Yeh ML, Lin YH, Liang PC, Liu SV, Hsieh MH, Lin ZY, Chen SC, Huang JF, Chuang WL, Dai CY, Yu ML. Role of IL-28B genetic variants in HCV-related liver disease severity in patients with different viral genotypes. Medicine (Baltimore) 2018;97:e9782. [PMID: 29517696 DOI: 10.1097/MD.0000000000009782] [Cited by in Crossref: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Salameh H, Masadeh M, Al Hanayneh M, Petros V, Maslonka M, Nanda A, Singal AK. PNPLA3 polymorphism increases risk for and severity of chronic hepatitis C liver disease. World J Hepatol 2016; 8(35): 1584-1592 [PMID: 28050240 DOI: 10.4254/wjh.v8.i35.1584] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
20 Semmler G, Binter T, Kozbial K, Schwabl P, Chromy D, Bauer D, Simbrunner B, Müllner-Bucsics T, Scheiner B, Stättermayer A, Pinter M, Steindl-Munda P, Trauner M, Ferenci P, Reiberger T, Mandorfer M. Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. J Pers Med 2021;11:281. [PMID: 33917196 DOI: 10.3390/jpm11040281] [Reference Citation Analysis]
21 Manchiero C, Nunes AKDS, Magri MC, Dantas BP, Mazza CC, Barone AA, Tengan FM. The rs738409 polymorphism of the PNPLA3 gene is associated with hepatic steatosis and fibrosis in Brazilian patients with chronic hepatitis C. BMC Infect Dis 2017;17:780. [PMID: 29258449 DOI: 10.1186/s12879-017-2887-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
22 Senkerikova R, Frankova S, Jirsa M, Kreidlova M, Merta D, Neroldova M, Chmelova K, Spicak J, Sperl J. PNPLA3 rs738409 G allele carriers with genotype 1b HCV cirrhosis have lower viral load but develop liver failure at younger age. PLoS One 2019;14:e0222609. [PMID: 31527889 DOI: 10.1371/journal.pone.0222609] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Huang CF, Yeh ML, Huang CY, Tsai PC, Ko YM, Chen KY, Lin ZY, Chen SC, Dai CY, Chuang WL, Huang JF, Yu ML. Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. Medicine (Baltimore) 2016;95:e4157. [PMID: 27399135 DOI: 10.1097/MD.0000000000004157] [Cited by in Crossref: 19] [Cited by in F6Publishing: 13] [Article Influence: 3.8] [Reference Citation Analysis]
24 Rüschenbaum S, Schwarzkopf K, Friedrich-Rust M, Seeger F, Schoelzel F, Martinez Y, Zeuzem S, Bojunga J, Lange CM. Patatin-like phospholipase domain containing 3 variants differentially impact metabolic traits in individuals at high risk for cardiovascular events. Hepatol Commun 2018;2:798-806. [PMID: 30027138 DOI: 10.1002/hep4.1183] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]